Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

Medicine & Life Sciences

• Trastuzumab 100%
• Colorectal Neoplasms 66%
• Drug Therapy 49%
• B 31 8%
• Diarrhea 8%
• Safety 6%
• Belgium 6%
• Colitis 5%
• Aspartate Aminotransferases 5%
• United States Food and Drug Administration 5%
• Therapeutics 5%
• Alanine Transaminase 5%
• Spain 5%
• Acute Kidney Injury 4%
• Italy 4%
• African Americans 4%
• France 4%
• Duration of Therapy 4%
• Fatigue 4%
• Disease Progression 4%
• Cohort Studies 3%
• Hypertension 3%
• Neoplasms 3%
• Population 2%